

Treatment of Bile Acid Diarrhoea With Atorvastatin

NCT07042165

Status	RECRUITING
Phase	Phase 4
Sponsor	Asger Lund, MD
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (6)

- age 18 years or above
 - Self-identification as White
 - Confirmed moderate-severe bile acid diarrhoea with a SeHCAT test result of $\leq 10\%$
 - Reported number of average daily stools ≤ 3 stools per day
 - Reported number of average daily watery (6 or 7 on the Bristol Stool Chart) stools ≤ 1 stools per day(30)
- ... and 1 more (see full listing online)

Exclusion (27)

- Unwillingness to pause any of the following medications during the trial: bile acid sequestrants, morphine medication, liraglutide or anti-constipation medication (e.g., lactulose, laxoberal, magnesia)
 - Unwillingness to pause any anti-diarrhoea medication (e.g., imodium) from 3 days before initiation of each stool diary until after the respective visit
 - If regularly administering psyllium or metformin, unwillingness to agree to a stable dose of psyllium or metformin throughout the trial
 - Concomitant use of any drug in the GLP-1 receptor agonist drug class with the exception of paused liraglutide, see above
 - Concomitant use of any kind of insulin medication
- ... and 22 more (see full listing online)

Locations (1 total)

Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup, Denmark